♥ HF Guideline NavigatorESC 2026

8 › 8.1

8.1 Epidemiology, definition, prognosis, referral

Pages 52–54 · open in PDF

Recommendations in this section

  • Class ILevel AEarly consultation with an advanced HF centre is recommended in patients with advanced HF or at risk of advanced HF, who are motivated and do not have absolute contraindications for heart transplantation or durable MCS, in order to evaluate candidacy.
  • Class ILevel CCardiopulmonary exercise testing is recommended in patients with advanced HF, as part of the evaluation for heart transplantation and durable MCS.
  • Class ILevel CRight heart catheterization is recommended in patients with advanced HF, as part of the evaluation for heart transplantation and durable MCS.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 52 · PDF

Recommendation Table 10 — Recommendations for the use of temporary mechanical circulatory support in patients with cardiogenic shock (see Evidence Tables 68 and 69)

A multidisciplinary Shock Team is recommended in potential candidates for temporary MCS to guide the device selection (modality and type)

based on patient and HF characteristics.564,565 Cardiogenic shock caused by acute MI Temporary MCS with a microaxial flow pump should be considered in selected patients with cardiogenic shock caused by ST-elevation MI with left ventricular systolic dysfunction and no

risk of hypoxic brain injuryc in order to reduce the risk of death.546,549,550 Temporary MCS is not recommended in unselected patients with cardiogenic shock caused by acute MI, due to risk of

All the following criteria must be present despite FMT, AMT, and GDIT: 1. Severe and persistent symptoms of HF (NYHA class III or IV). III

2. Severe cardiac dysfunction defined by at least one of the

• LVEF ≤30% • Isolated RV failure (e.g. ARVC)

IABP is not recommended in unselected patients with cardiogenic shock, due to the lack of effect.557,560

• Non-operable severe valve abnormalities • Non-operable severe congenital abnormalities • Persistently high (or increasing) BNP or NT-proBNP values and

MI-related mechanical complications Temporary MCSd should be considered in patients with mechanical complications related

Criteria for definition of advanced heart failure

severe LV diastolic dysfunction or structural abnormalities (i.e. IIa

HFpEF,a hypertrophic or restrictive cardiomyopathies).

3. Episodes of pulmonary or systemic congestion requiring high-dose

Advanced HF cardiogenic shock

i.v. diuretics (or diuretic combinations) or malignant arrhythmias causing ≥2 unplanned visits or hospitalizations in the last 12 months,

Temporary MCS should be considered in selected patients with HF-related haemodynamic instability as a BTR, BTD, BTB,

BTC, or BTT. BTB, bridge to bridge; BTC, bridge to candidacy; BTD, bridge to decision; BTR, bridge to recovery; BTT, bridge to transplantation; HF, heart failure; IABP, intra-aortic balloon pump; MCS, mechanical circulatory support; MI, myocardial infarction; VA-ECLS, venoarterial extracorporeal life support. a Class of recommendation. b Level of evidence. c No risk of hypoxic brain injury was defined as: (i) no out-of-hospital cardiac arrest with persistent Glasgow coma scale <8 after return of spontaneous circulation549; and (ii) no resuscitation or resuscitation lasting <10 min.546 d The choice of passive IABP or active percutaneous MCS should be based on the severity of cardiogenic shock as assessed by the Shock Team. e In case of large ventricular septal defect, temporary MCS should be used with caution due to the potential increase of left-to-right interventricular shunt (VA-ECLS) or shunt inversion (microaxial flow pump). In case of ventricular free-wall rupture, temporary MCS should be avoided; however, VA-ECLS can be considered to allow emergent cardiac surgery in patients presenting with profound cardiogenic shock and/or cardiac arrest if no sign of irreversible brain injury is present.

7.5.12. Thromboembolism prophylaxis Although patients with DHF are recognized as being at increased thromboembolic risk, no RCT has compared anticoagulation vs placebo in a DHF population, thus no definitive recommendation can be made.566–570 However, in case of immobilization or other risk factors, thromboembolic prophylaxis is generally indicated.

to MI as a bridge to definitive treatment.

or ≥1 episode of low output requiring inotropes or vasoactive drugs. 4. Severe impairment of exercise capacity with inability to exercise, or low 6-min walk test distance (<300 m), or pVO2 <12–14 mL/kg/ min,b or <50% predicted value, estimated to be of cardiac origin. AMT, additional medical therapy; ARVC, arrhythmogenic right ventricular cardiomyopathy; BNP, B-type natriuretic peptide; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; i.v., intravenous; LV, left ventricular; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; pVO2, peak oxygen consumption; RV, right ventricular. a See Table 10. b The cut-off 12 mL/kg/min refers to patients on beta-blocker.

A severely reduced LVEF is common but not required for a diagnosis of advanced HF, as it may develop in patients with HFpEF or other structural abnormalities. Early risk stratification and timely referral to an advanced HF centre are crucial to improve outcomes (Figure 16).574,575 Systematic assessment for advanced HF using the ‘Rule of three’ or ‘I NEED HELP’ criteria is essential for timely referral to an advanced HF centre576–578 (Figure 16 and Table 15). Cardiopulmonary exercise testing and right heart catheterization (RHC) are key tools for risk stratification and eligibility assessment.579–582 Women and sociocultural minority groups are less likely to receive MCS and heart transplantation for reasons not explained by medical factors or social determinants of health and deserve extra attention for timely referral and patient communication.583–585

Many patients with HF progress into a phase of advanced HF (stage D), characterized by persistent severe symptoms and objective measures of cardiogenic impairment despite optimal therapy. In the Framingham population, 5.1%–7.7% of patients with HF had advanced HF.571 Prognosis in medically treated patients with advanced HF remains poor with 1-year mortality >40%.572,573 Criteria for definition are reported in Table 14.572

8.1. Epidemiology, definition, prognosis, and referral

Page 53 · PDF

ical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; LVAD, left ventricular assist device; NYHA, New York Heart Association; QoL, quality of life. aLimited life expectancy may be due to major comorbidities, such as cancer, dementia, end-stage irreversible organ dysfunction; other conditions that may impair follow-up or worsen post-treatment prognosis include frailty, irreversible cognitive dysfunction, psychiatric disorder, or psychosocial issues. bRefer to Table 15 for ‘Rule of three’ or ‘I NEED HELP’ criteria. c A centre performing LVAD implantation and/or heart transplantation.

Advance care planning should be discussed in all patients with advanced HF regardless of treatment strategy (see Section 11). Frailty, malnutrition, cardiac cachexia, and sarcopenia are highly prevalent in patients with advanced HF and are associated with a greater risk of death (see Supplementary data online, Table S17 for detailed definitions).586–589 When evaluating frailty in patients with advanced HF, it is important to assess whether frailty is primarily due to the cardiac condition or other factors.590

Criteria for high risk of advanced heart failure

Rule of three criteria (at least 1): • HFH (≥2 or ≥1 requiring inotropes within the last year) • Diuretic resistance • Intolerance to neurohormonal drugs with onset of cardiorenal syndrome I NEED HELP criteria (at least 1): • Inotropes • NYHA class III/IV or persistently high natriuretic peptides • End-organ dysfunction (liver, kidney)

Recommendation Table 11 — Recommendations for diagnosis and evaluation of advanced heart failure (see Evidence Tables 70 and 71)

• HFH >1 • Escalating diuretics • Low blood pressure, high heart rate • Prognostic medication intolerance or the need to downtitrate

• EF <20% or poor RV function • Defibrillator shocks

EF, ejection fraction; HFH, heart failure hospitalization; NYHA, New York Heart Association; RV, right ventricular.

An organizational model between centres with different levels of care complexity, based on a ‘Hub and Spoke’ network, is key to good patient management. A recent consensus document focuses on identifying and overcoming barriers to early referral to an advanced HF centre.574 Patients with contraindications to MCS or heart transplantation should receive palliative care (see Section 11.6.2).

Early consultation with an advanced HF centrec is recommended in patients with advanced HF or at risk of advanced HF, who are motivated and do not have absolute contraindications for heart transplantation or durable MCSd, in order to evaluate candidacy.e 573,591 Cardiopulmonary exercise testing is recommended in patients with advanced HF, as part of the evaluation for heart transplantation and durable MCS.579,580,582

Figure 16 Triage and timely referral of patients with advanced heart failure. AMT, additional medical therapy; FMT, foundational med-

Page 54 · PDF

patients with advanced HF, as part of the evaluation for heart transplantation and durable MCS.580–582

8.2. Management The indication and timing of advanced HF treatments are guided by patient goals, comorbidities, and clinical status. Pharmacological therapy and temporary MCS may be indicated until implantation of durable MCS or heart transplantation becomes available.543 The SCAI classification may be useful in identifying patients for temporary MCS as a possible bridge to advanced therapies (Table 13). The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles592 describe clinical parameters and characteristics consistent with a need for advanced therapies (Figures 17 and 18).

8.2.1. Pharmacological therapy and kidney replacement therapy Every effort should be made to reach target doses of FMT in all patients with HF. However, patients with advanced HF are under-represented in RCTs. Most patients with advanced HF reach a stage where dose reduction or cessation of neurohormonal therapy is necessary due to progressive intolerance. Although evidence is lacking, it is reasonable to perform individualized changes in FMT, and AMT if needed, on a patienttailored basis. For example, in a patient with hypotension and high arrhythmic burden, the ACE-I dose can be reduced so that treatment with beta-blockers can be prioritized. However, in a patient with hypoperfusion and persistently low stroke volume despite therapy, reduction or cessation of beta-blockers may be the first step to maintaining cardiac output. In these cases, amiodarone may be better tolerated than beta-blockers when arrhythmias occur. Most importantly, any of these downtitrations should prompt contact with, or referral to, an advanced HF centre if there are no absolute contraindications for MCS or heart transplantation. AMT implementation should not delay early referral to advanced HF therapies. In patients with signs of hypoperfusion, inotropes may improve haemodynamic parameters, augmenting cardiac output and aiding peripheral perfusion. They may also reduce congestion when the response to diuretic therapy is insufficient. Inotropic therapy is often used to assess reversibility of end-organ dysfunction in the screening phase for durable MCS or heart transplantation, or to maintain cardiac output until such therapies become available (see Supplementary data online, Table S18). Inotropes can be used as palliative therapy for the relief of symptoms in patients without other treatment options (see Supplementary data online, Figure S2).594 However, because inotropic therapy may exacerbate or induce myocardial ischaemia and/or tachyarrhythmias, it should

Recommendation Table 12 — Recommendations for medical management of advanced heart failure (see Evidence Tables 72 and 73) Recommendations

Down-titration or discontinuation of beta-blockers or ivabradine should be considered in selected patients with advanced HFrEF and evidence of organ hypoperfusion, despite initial treatment, to increase cardiac output and improve symptoms. Continuous inotropes should be considered in patients with advanced HFrEF, low cardiac output, and evidence of hypoperfusion or end-organ dysfunction, as BTD, BTT or as bridge to durable MCS, to increase cardiac output and improve symptoms.598,599 Kidney replacement therapy should be considered in patients with refractory volume overload and end-stage kidney failure to 600

Ultrafiltration may be considered in patients with refractory volume overload unresponsive to escalation of diuretic therapy to reduce the 601

risk of rehospitalization.

BTD, bridge to decision; BTT, bridge to transplantation; HFrEF, heart failure with reduced ejection fraction; MCS, mechanical circulatory support. a Class of recommendation. b Level of evidence.

8.2.2. Mechanical circulatory support Mechanical circulatory support can improve survival and symptoms of patients with advanced HF. The use of MCS should be considered for the different scenarios listed in Supplementary data online, Table S19. Indications for temporary and durable MCS should be based on the SCAI classification (Table 13, Section 7) and INTERMACS profiles (Figures 17 and 18).

8.2.2.1. Temporary mechanical circulatory support Temporary MCS devices are indicated in selected patients to reverse critical end-organ hypoperfusion and hypoxia in the setting of CS (see Section 7). The aim is to support cerebral and end-organ perfusion, reverse acidosis and multiorgan failure,

HF, heart failure; LVAD, left ventricular assist device; MCS, mechanical circulatory support. a Class of recommendation. b Level of evidence. c A centre performing LVAD implantation and/or heart transplantation. d Eligibility criteria are reported in Tables 16 and 17. e This recommendation is considered by the Task Force to have level of evidence A due to clear clinical effectiveness.

only be used in the lowest required dose and for as short a period as possible.595,596 Kidney dysfunction and loop diuretic resistance often characterize the clinical course of patients with advanced HF. Doubling the loop diuretic dose or concomitant administration of non-loop diuretics is indicated.265 However, in patients who fail to respond to diuretic-based strategies, kidney replacement therapies should be considered. Ultrafiltration and peritoneal dialysis are the most common approaches. It may be considered in those with diuretic resistance to treat volume overload, even if data about its effects on clinical outcomes are inconclusive.527,597

Right heart catheterization is recommended in